The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Cancer
Conventional dendritic cells
Cross-presenting dendritic cells
Dendritic cells
Immunotherapy
Myeloid dendritic cells
Natural dendritic cells
Plasmacytoid dendritic cells
Vaccination
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
18 04 2019
18 04 2019
Historique:
received:
11
02
2019
accepted:
26
03
2019
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
8
7
2020
Statut:
epublish
Résumé
Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response. DC vaccination remains a promising approach with the potential to further improve cancer immunotherapy with little or no evidence of treatment-limiting toxicity. However, evidence for objective clinical antitumor activity of DC vaccination is currently limited, hampering the clinical implementation. One possible explanation for this is that the most commonly used monocyte-derived DCs may not be the best source for DC-based immunotherapy. The novel approach to use naturally circulating DCs may be an attractive alternative. In contrast to monocyte-derived DCs, naturally circulating DCs are relatively scarce but do not require extensive culture periods. Thereby, their functional capabilities are preserved, the reproducibility of clinical applications is increased, and the cells are not dysfunctional before injection. In human blood, at least three DC subsets can be distinguished, plasmacytoid DCs, CD141
Identifiants
pubmed: 30999964
doi: 10.1186/s40425-019-0580-6
pii: 10.1186/s40425-019-0580-6
pmc: PMC6471787
doi:
Substances chimiques
Antigens, CD1
0
CD1C protein, human
0
Cancer Vaccines
0
Glycoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Références
Cancer Res. 2009 Apr 1;69(7):2927-34
pubmed: 19318559
Curr Opin Immunol. 2003 Apr;15(2):138-47
pubmed: 12633662
Cell. 2001 Aug 10;106(3):259-62
pubmed: 11509173
J Immunother. 2002 Sep-Oct;25(5):429-38
pubmed: 12218781
Cancer Immunol Immunother. 2016 Mar;65(3):327-39
pubmed: 26861670
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Clin Cancer Res. 2016 May 1;22(9):2155-66
pubmed: 26712687
Oncoimmunology. 2015 Jun 5;5(1):e1057673
pubmed: 26942068
Blood. 2013 Jan 17;121(3):459-67
pubmed: 23212525
Blood. 2002 Dec 15;100(13):4512-20
pubmed: 12393628
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
J Immunol Res. 2015;2015:253191
pubmed: 25815345
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
J Clin Invest. 2008 Jun;118(6):2098-110
pubmed: 18497879
J Clin Oncol. 2006 Jul 1;24(19):3089-94
pubmed: 16809734
Front Immunol. 2013 Nov 12;4:372
pubmed: 24282405
J Clin Invest. 2008 Mar;118(3):1165-75
pubmed: 18259609
Mol Immunol. 2011 Mar;48(6-7):810-7
pubmed: 21257206
J Immunother Cancer. 2018 Sep 29;6(1):96
pubmed: 30268156
Nat Rev Immunol. 2007 Oct;7(10):790-802
pubmed: 17853902
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Nat Biotechnol. 2005 Nov;23(11):1407-13
pubmed: 16258544
Clin Cancer Res. 2009 May 15;15(10):3366-75
pubmed: 19417017
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768
pubmed: 27837020
Nat Immunol. 2004 Dec;5(12):1219-26
pubmed: 15549123
Expert Rev Clin Immunol. 2014 Jul;10(7):915-26
pubmed: 24758519
J Exp Med. 2001 Jan 15;193(2):233-8
pubmed: 11208863
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
J Immunol. 2007 Feb 1;178(3):1534-41
pubmed: 17237402
Blood. 2011 Dec 22;118(26):6836-44
pubmed: 21967977
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Cancer Res. 2013 Jan 1;73(1):19-29
pubmed: 23087058
Cancer Immunol Immunother. 2010 Oct;59(10):1573-82
pubmed: 20204387
Ann Oncol. 2013 Oct;24(10):2686-2693
pubmed: 23904461
Clin Cancer Res. 2009 Apr 1;15(7):2531-40
pubmed: 19318472
Cancer Res. 2016 Aug 1;76(15):4332-46
pubmed: 27325645
Front Immunol. 2014 May 22;5:239
pubmed: 24904587
Semin Cell Dev Biol. 2015 May;41:39-48
pubmed: 24910448
Clin Cancer Res. 2011 Sep 1;17(17):5725-35
pubmed: 21771874
Clin Cancer Res. 2003 Nov 1;9(14):5091-100
pubmed: 14613986
J Immunol. 2004 Jan 15;172(2):857-63
pubmed: 14707056
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Vaccines (Basel). 2020 Nov 10;8(4):
pubmed: 33182610
Cancer Immunol Immunother. 2012 Aug;61(8):1279-88
pubmed: 22294456
Cancer Res. 2003 Jan 1;63(1):12-7
pubmed: 12517769
J Exp Med. 2010 Jun 7;207(6):1273-81
pubmed: 20479115
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
J Exp Med. 2010 Jun 7;207(6):1261-71
pubmed: 20479117
Blood. 2013 Aug 8;122(6):932-42
pubmed: 23794066
J Immunol. 2000 Dec 1;165(11):6037-46
pubmed: 11086035
Immunity. 2017 Feb 21;46(2):205-219
pubmed: 28190711
J Immunother. 2015 Feb-Mar;38(2):71-6
pubmed: 25658616
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
Immunol Rev. 2010 Mar;234(1):177-98
pubmed: 20193019
Cancer Immunol Immunother. 2015 Nov;64(11):1461-73
pubmed: 26275446
PLoS One. 2011 Apr 20;6(4):e18801
pubmed: 21533099
J Transl Med. 2018 May 29;16(1):142
pubmed: 29843811
PLoS One. 2017 Apr 14;12(4):e0175712
pubmed: 28410380
Cancer Immunol Immunother. 2006 Nov;55(11):1432-42
pubmed: 16612595
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798
Tissue Antigens. 1999 Apr;53(4 Pt 1):320-34
pubmed: 10323336
Annu Rev Immunol. 2005;23:975-1028
pubmed: 15771591
J Clin Oncol. 2005 Aug 20;23(24):5779-87
pubmed: 16110035
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Clin Cancer Res. 2017 Nov 15;23(22):6764-6770
pubmed: 28663235
Semin Immunol. 2010 Jun;22(3):173-82
pubmed: 20409732
Nat Immunol. 2000 Oct;1(4):305-10
pubmed: 11017101
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Cell Rep. 2016 Sep 13;16(11):2953-2966
pubmed: 27626665
J Immunol. 2004 Jun 1;172(11):7162-8
pubmed: 15153540
J Exp Med. 2010 Jun 7;207(6):1283-92
pubmed: 20479118
J Immunother. 2008 Oct;31(8):771-80
pubmed: 18779742
Cancer Res. 2012 Dec 1;72(23):6102-10
pubmed: 23010076
J Exp Med. 2006 Jul 10;203(7):1629-35
pubmed: 16785312
J Clin Oncol. 2016 Apr 20;34(12):1330-8
pubmed: 26926680
J Immunother. 2007 Oct;30(7):740-8
pubmed: 17893566
J Exp Med. 2004 Feb 16;199(4):567-79
pubmed: 14970182
Cancer Immunol Immunother. 2003 Oct;52(10):583-91
pubmed: 12827310
Immunity. 2012 Jul 27;37(1):60-73
pubmed: 22795876
Cancer Immunol Immunother. 2007 Oct;56(10):1513-37
pubmed: 17503040
J Exp Med. 2010 Nov 22;207(12):2703-17
pubmed: 20975040
J Immunol. 2015 Jul 1;195(1):367-76
pubmed: 26026061
Nat Med. 2001 Jun;7(6):649-52
pubmed: 11385492
J Control Release. 2010 Jun 1;144(2):118-26
pubmed: 20156497
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
J Immunol. 2012 Oct 1;189(7):3299-310
pubmed: 22925929
J Exp Med. 2001 Sep 17;194(6):769-79
pubmed: 11560993
J Exp Med. 2003 Oct 6;198(7):1023-34
pubmed: 14530375
J Immunol Methods. 2003 Mar 1;274(1-2):47-61
pubmed: 12609532
J Invest Dermatol. 2012 Oct;132(10):2395-2406
pubmed: 22696054
Blood. 2009 Apr 30;113(18):4232-9
pubmed: 19176317
Blood. 2004 Sep 15;104(6):1808-15
pubmed: 15166034
Immunology. 2013 Sep;140(1):22-30
pubmed: 23621371
J Leukoc Biol. 2005 Oct;78(4):898-908
pubmed: 16037410
J Exp Med. 1973 May 1;137(5):1142-62
pubmed: 4573839
Nat Med. 1996 Jan;2(1):52-8
pubmed: 8564842
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633